The study sought to evaluate the clinical, endocrinologic, and ultrasonographic features in 150 Singaporean adolescent @entity1 with @entity3610 ( @entity3610 ) before and after treatment, which was composed primarily of a combined hormone therapy of @entity172 and @entity3429 . The @entity1 ' ages ranged from 12 to 22 years with the majority between 15 and 18 years of age. Most of these @entity1 were seen between their third and fifth gynecologic year. A considerable proportion of them had matured early, experiencing menarche between 9 and 12 years of age. Tanner staging was normal except for a greater proportion at higher stages for pubic and axillary hair, most likely a reflection of the substantial degree of androgenization commonly found in subjects with @entity3610 . All 150 @entity1 presented with @entity1866 including secondary @entity2588 , menarche only, anovulatory uterine @entity548 , @entity2589 , and primary @entity2588 . The majority had normal body weight; 10% to 27% were either underweight or overweight, respectively. On ultrasound, @entity1 presented with enlarged ovaries; enlargement was more pronounced in the right ovary with dense stroma and multiple subcapsular cysts. Many subjects had elevated @entity342 , luteinizing hormone (LH), and LH/ follicle-stimulating hormone (FSH) levels. Although characteristic of @entity3610 , FSH levels were either low or normal. Prolactin, @entity53 , @entity9027 ( @entity2990 ), and @entity2671 were generally normal. A substantial proportion of the study group had elevated @entity701 levels. It was noted that adolescent @entity1 with @entity3610 responded well to treatment; more than 60% showed improvement in cycle profiles following at least 1 year of treatment. Our current opinion is that adolescents with @entity3610 should be managed early, and that treatment should include medical correction of any hormonal or body-weight imbalance and include psychologic intervention when necessary.

Clinical, endocrinologic, and ultrasonographic features of XXXX in Singaporean adolescents.

@entity1 :: ('9606', 'Species') :: ['patients', 'girls'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity3610 :: ('MESH:D011085', 'Disease') :: ['polycystic ovary syndrome', 'PCOS'] @entity3429 :: ('MESH:D017373', 'Chemical') :: ['cyproterone acetate'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity2990 :: ('CHEBI:16814', 'Chemical') :: ['DHEAS'] @entity2671 :: ('MESH:D000735', 'Chemical') :: ['androstenedione'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol'] @entity1866 :: ('MESH:D008599', 'Disease') :: ['menstrual disorders'] @entity2589 :: ('MESH:D009839', 'Disease') :: ['oligomenorrhea'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol'] @entity9027 :: ('MESH:D019314', 'Chemical') :: ['dehydroepiandrosterone sulfate'] @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea']
@entity3610 :: (MESH:D011085,Disease) :: ['polycystic ovary syndrome']
